At close: January 3 at 4:00:02 PM EST
Pre-Market: 8:01:20 AM EST
Breakdown
TTM
7/31/2024
7/31/2023
7/31/2022
7/31/2021
Operating Expense
29,979.8800
33,330.0760
23,272.2640
15,285.5530
6,972.3440
Operating Income
-29,979.8800
-33,330.0760
-23,272.2640
-15,285.5530
-6,972.3440
Net Non Operating Interest Income Expense
110.2530
288.0180
891.2130
135.7520
-75.4050
Other Income Expense
13,149.9310
28,110.5100
2,078.6570
-11,689.1020
-6,768.4510
Pretax Income
-16,719.6960
-4,931.5480
-20,302.3940
-26,838.9030
-13,816.2000
Net Income Common Stockholders
-16,595.1840
-4,791.4660
-20,302.3940
-26,838.9030
-13,816.2000
Diluted NI Available to Com Stockholders
-2,313.1060
-4,791.4660
-20,302.3940
-26,838.9030
-13,816.2000
Basic EPS
-0.89
-0.29
-1.30
-1.73
-0.09
Diluted EPS
-0.89
-0.29
-1.30
-1.73
-0.09
Basic Average Shares
19,119.7600
16,454.9320
15,619.6760
15,494.0910
4,519.5790
Diluted Average Shares
19,119.7600
16,454.9320
15,619.6760
15,494.0910
4,519.5790
Total Operating Income as Reported
-29,979.8800
-33,330.0760
-23,272.2640
-15,288.9410
-6,973.4980
Rent Expense Supplemental
--
--
--
--
11.9390
Total Expenses
29,979.8800
33,330.0760
23,272.2640
15,285.5530
6,972.3440
Net Income from Continuing & Discontinued Operation
-16,595.1840
-4,791.4660
-20,302.3940
-26,838.9030
-13,816.2000
Normalized Income
-29,923.1400
-33,008.4860
-22,381.0510
-15,149.8010
-7,047.7490
Interest Income
110.2530
288.0180
891.2130
136.7310
3.1490
Interest Expense
--
--
--
0.9790
78.5540
Net Interest Income
110.2530
288.0180
891.2130
135.7520
-75.4050
EBIT
-29,979.8800
-33,330.0760
-23,272.2640
-26,837.9240
-13,737.6460
EBITDA
-29,873.1440
-33,246.1790
-23,256.9930
-26,822.6520
-13,722.3900
Reconciled Depreciation
106.7360
83.8970
15.2710
15.2720
15.2560
Net Income from Continuing Operation Net Minority Interest
-16,595.1840
-4,791.4660
-20,302.3940
-26,838.9030
-13,816.2000
Total Unusual Items Excluding Goodwill
13,327.9560
28,217.0200
2,078.6570
-11,689.1020
-6,768.4510
Total Unusual Items
13,327.9560
28,217.0200
2,078.6570
-11,689.1020
-6,768.4510
Normalized EBITDA
-43,201.1000
-61,463.1990
-25,335.6500
-15,133.5500
-6,953.9390
7/31/2021 - 3/14/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CDIO Cardio Diagnostics Holdings, Inc.
0.9560
+9.38%
DRMA Dermata Therapeutics, Inc.
1.4300
+2.88%
KLTO Klotho Neurosciences, Inc.
0.6000
-14.22%
QNRX Quoin Pharmaceuticals, Ltd.
0.7003
+4.29%
VRPX Virpax Pharmaceuticals, Inc.
0.4210
+12.42%
ALZN Alzamend Neuro, Inc.
1.2600
+5.00%
ERNA Eterna Therapeutics Inc.
0.3440
-6.78%
XFOR X4 Pharmaceuticals, Inc.
0.7421
-1.32%
TVGN Tevogen Bio Holdings Inc.
1.1200
+5.66%
VRAX Virax Biolabs Group Limited
2.4300
+9.95%